Press Releases

Mar 10, 2021
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025    read more...
Mar 05, 2021
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer    read more...
Mar 02, 2021
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia    read more...
Feb 26, 2021
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan    read more...
Feb 25, 2021
BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results    read more...
Feb 17, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists    read more...
Feb 17, 2021
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia    read more...
Jan 27, 2021
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma    read more...
Jan 13, 2021
China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer    read more...
Jan 11, 2021
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab    read more...
Jan 11, 2021
Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology    read more...
Jan 07, 2021
BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference    read more...
Dec 27, 2020
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)    read more...
Dec 07, 2020
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)    read more...
Dec 07, 2020
BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenström’s Macroglobulinemia at the 62nd ASH Annual Meeting    read more...
Dec 06, 2020
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting    read more...
Dec 01, 2020
BeiGene Announces Pricing of Public Offering by Selling Shareholders    read more...
Dec 01, 2020
BeiGene Launches Proposed Public Offering by Selling Shareholders    read more...
Nov 23, 2020
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference    read more...
Nov 19, 2020
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma    read more...